A Phase 3 readout for AstraZeneca and Ionis’ Wainua (eplontersen) has failed in transthyretin amyloid cardiomyopathy, further constricting development options for TTR-silencing approaches in ATTR-CM. Coverage of the decision and ensuing analysis highlighted how Wall Street is parsing whether the failure reflects knockdown versus stabilizer synergy—or the modality itself—after the Cardio-TTRansform program reduced TTR levels but did not clear its clinical endpoint.